Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer
Figure 6
CCNE1 copy number and gene expression associated with patient outcome.
(A) Patient age distribution stratified by CCNE1 amplification status. Kruskal-Wallis p-value reported, bars indicate mean and SEM. (B) Correlation between CCNE1 copy number by qPCR and gene expression signal by microarray. (C) Kaplan-meier analysis of CCNE1 unamplified (n = 68), gained (n = 21) and amplified (n = 6) ovarian cancer patients and (D) CCNE1 low (n = 31), medium (n = 28) and high (n = 36) expressing samples for progression-free survival and (E & F) overall survival. Log-rank test p-values reported. Stratification by CCNE1 copy number or expression status described in Materials and Methods.